The high cost of pharmaceuticals often means only the richest patients get lifesaving medicines. As coronavirus drugs emerge, it will require hard, creative work to ensure they’re available to all.
Articles on Drug prices
Displaying 21 - 40 of 48 articles
A program intended to reduce coca production ended up giving two Latin American countries a big boost to their flower power.
Toilet paper shortages were bad enough. A shortage of drugs during the COVID-19 pandemic would be worse. A provision in the Canadian government’s relief package aims to prevent that from happening.
As drug prices soar, consumers look for cheaper generics. A recent study showed safety issues in some generics made abroad, however, suggesting that the FDA’s honor system may not be enough to ensure safety.
NHS drug budgets could rise by billions of pounds a year after a US-UK trade deal.
Michael Gove claims that drug prices are not on the negotiating table.
Politicians and even HHS are now discussing ways to allow US consumers to buy drugs from Canada. Here’s why it’s not as simple as it seems.
Presidential candidates and the current president have all talked about ways to lower drug costs, but experts know it is going to take more than politics to change how drugs are priced in the US.
President Trump has been backing transparency in hospital pricing so that consumers can compare prices. But will that help when the real deals are done in secret?
Biologics, therapies made inside or of living cells, are a growing share of pharmaceutical sales. But the cost of these miracle treatments makes them unaffordable for many. New FDA guidance may help.
As concern grows for the escalating prices of prescription drugs, a novel approach to lower the price of drugs to treat hepatitis C in Louisiana holds promise, a policy expert says.
The Trump administration’s proposal to lower drug prices focuses on discounts. A health policy scholar argues that the US could learn from Europe’s system of measuring drug value and effectiveness.
The logic behind U.S. president Donald Trump’s proposal that Canada and other countries have been “free-riding” off high prices in the United States is bizarre at best.
The rising costs of generic drugs have led to outcries. In a search for solutions, four hospital systems are proposing to make drugs on their own. Could their idea work?
The cost of a life-saving drug in Canada is rising by 3,000 per cent. A national pharmacare plan could bring order to this chaotic world of Canadian drug prices.
Have you ever wondered why some drugs are so cheap, and others so expensive? Here’s why.
Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here’s where they come from and how they work.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies’ own finances.
An independent expert provides his pick of the most notable drugs added to the PBS on May 1, 2017.
The Orphan Drug Act was enacted 34 years ago to encourage the development of drugs for rare diseases. Drug companies were guaranteed seven years of exclusivity. Then the rush was on to run up prices.
Top contributors
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of Health Economics, Flinders University
-
Research Fellow, Flinders University
-
Associate Professor of Public Health, The Ohio State University
-
Adjunct associate, Lancaster University
-
Associate Professor in Health Economics, Flinders University
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Professor of Bioethics, Macquarie University
-
Associate Professor of Law, Washington University in St. Louis
-
Professor of Public Health, La Trobe University
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Macquarie University Research Fellow, Macquarie University
-
Adjunct Associate Professor, School of Social and Political Sciences, University of Sydney
-
Dean of the Sol Price School of Public Policy; Distinguished Professor of Pharmacy, Public Policy, and Economics, University of Southern California